Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.
CA 02914479 2015-12-03
WO 2015/014731
PCT/EP2014/065991
-1-
Method for differentiation of pluripotent stem cells into multi-competent
renal precursors
FIELD OF THE INVENTION
This application relates to a method for differentiating pluripotent stem
cells (PSCs) into
defined multi-competent renal precursor cells expressing Six2. These renal
precursor cells are
able to differentiate into fully functional and fully differentiated
podocytes. Moreover this
application relates to a method for differentiating human embryonic stem cells
(ESCs) and
induced pluripotent stem cells (iPSCs) into defined renal precursor cells
expressing Six2 and
podocytes based on linked steps of chemically defined medium inductions.
BACKGROUND
Renal cells are used in basic research, disease models, tissue engineering,
drug screening,
and in vitro toxicology. The kidneys have highly differentiated and
complicated structures, and
have pivotal roles in many physiological processes, such as body fluid
osmolality, regulation of
fluid and electrolyte balance, regulation of acid¨base balance, excretion of
metabolic waste
products and foreign chemicals, and production of hormones controlling blood
pressure and
erythropoiesis. Once damaged, kidneys rarely recover their functions. Renal
cells (e.g. Podocytes
and tubular cells) can regenerate to some extent following acute necrosis.
However, kidneys
generally do not regenerate in patients with chronic kidney diseases
(Humphreys and Bonventre,
2007), leading to end-stage renal insufficiency. Chronic kidney disease (CKD)
is a major cause
of morbidity and mortality affecting 11% of the adult population in Western
countries. People
with CKD suffer from a substantial loss of quality of life. The
pharmacoeconomic burden caused
by this disease is very high, as there is a permanent shortage of donor
kidneys for transplantation.
The mammalian kidney is derived from the intermediate mesoderm (IM), which
gives rise
to the nephric duct (ND), and the metanephric mesenchyme (MM). The ND gives
rise to the
collecting duct system, which is composed of two key cell types, principal
cells, and intercalated
cells. The MM specifies the cap mesenchyme (CM) and also gives rise to the
stroma. The CM is
the nephron progenitor population and differentiates in the renal vesicle via
a mesenchyme-to-
epithelial transition.
The nephron consists of a glomerular tuft or glomerulus, and a renal tubule.
The
glomerulus is a highly specialized filtration unit that separates waste
products for excretion as
urine. The filtration barrier between blood and urine in the glomerulus is
provided by highly
specialized, terminally differentiated cells termed podocytes.
CA 02914479 2015-12-03
WO 2015/014731
PCT/EP2014/065991
-2-
Converging evidence suggests that damage to the podocytes is one of the key
events
triggering loss of renal function. Podocyte damage occurs secondary to
hyperinsulinemia,
hemodynamic mechanisms and other mechanisms. The progressive loss of podocytes
leads to
broad sclerosis of the glomeruli accompanied by increased proteinuria and
reduction in the
clearance function (Wiggins, 2007).
However, the underlying mechanisms of insulin resistance and loss of
regenerative properties
leading to pathophysiological changes in the nephron of the kidney are not
completely
understood. Thus there is a need for in vitro cell models to study the biology
of renal diseases
like CKD and to facilitate the development of new treatments.
Embryonic stem (ES) cells and patient specific induced pluripotent stem cells
(iPSCs) are a
potential source for the production of renal precursor cells and podocytes in
large scale for
regenerative medicine and disease modeling for drug discovery. With the
induced pluripotent
stem cells (iPSCs) technology (Takahashi, K. & Yamanaka, S.,"Induction of
pluripotent stem
cells from mouse embryonic and adult fibroblast cultures by defined factors",
Cell 126, 663-676
(2006)) somatic cells can be reprogrammed to iPSCs by transduction of four
defined factors
(Sox2, Oct4, K1f4, c-20 Myc). The iPSC technology enables the generation of
patient specific
iPSCs, which can be differentiated into patient specific renal cells. These
patient specific renal
cells are useful for example in vitro modeling of the pathophysiology of renal
disease such as
Chronic Kidney Disease (CKD), Focal segmental glomerulosclerosis (FSGS),
Membranoproliferative glomerulonephritis, Polycystic kidney disease (PKD) and
diabetic
nephropathy associated with Diabetes Type-2, or for the assessment of drug
toxicity. One
important prerequisite to attempt such in vitro disease modeling is the
implementation of an
efficient, robust and scalable differentiation system (Tiscornia et al.,
2011).
Previous efforts to differentiate human PSCs into renal cells have not
achieved scales and
efficacies relevant for drug discovery campaigns or regenerative cell
therapies, neither in humans
(Batchelder et al., 2009; Lin et al., 2010; Mae et al., 2013; Narayanan et
al., 2013; Song et al.,
2012) or mice (Kim and Dressler, 2005; Mae et al., 2010; Morizane et al.,
2009; Nishikawa et al.,
2012; Ren et al., 2010). In addition, a major concern is the mal-
differentiation of the cells into
unwanted tissues or even the formation of teratomas. To avoid this danger, one
must direct the
cells to a state of differentiation that will on the one hand provide them
with the potential to
regenerate mature kidney cells of interest and on the other hand prevent mal-
differentiation. This
can be achieved by the controlled activation of the correct network of nephric
transcription
CA 02914479 2015-12-03
WO 2015/014731
PCT/EP2014/065991
-3-
factors. Unfortunately, attaining this exact state of differentiation in vitro
has proven to be quite
difficult. Many attempts have been made to induce pluripotent cells in this
manner, applying
both growth factor combinations [bone morpho genetic protein
(BMP)/Activin/Retinoic acid] and
genetic approaches. However, most differentiation studies, even after
successfully inducing renal
lineage genes, failed to pinpoint the exact stage in nephrogenesis (IM, MM,
CM) to which ESCs
were differentiated along the renal lineage.
Therefore, a highly efficient and chemically defined method for stimulating
the differentiation of
human pluripotent stem cells into kidney lineages remains to be developed.
Mae et al. 2013 describe a protocol to differentiate human pluripotent stem
cells into
intermediate mesoderm cells which express Osrl using defined induction steps
in serum free
media. The authors dissociated the undifferentiated cells with Accutase to
obtain a single layer of
cells and induced the differentiation with Activin A, a GSK3 beta inhibitor
and a ROCK kinase
inhibitor in a first step and BMP7 and the GSK3 beta inhibitor in a second
step. The authors
obtained 90 % Osrl positive cells on day 11 only. Expression of PAX2, LIM1,
WT1, CITED2,
EYA1 and SALL1 (marker genes for the developing kidney, gonad and adrenal
cortex) was
observed after 18 days, indicating that the authors obtained a heterogeneous
cell population of
different cell types and cells in different differentiation stages.
Lin et al., 2010 describe the differentiation of human embryonic stem cells
into mesodermal
renal progenitor lineages by reducing serum concentration and feeder layer
density for 14 days.
The authors obtained a heterogeneous population of differentiated human
embryonic cells which
they fractionated by flow cytometry.
Batchelder et al., 2009 describe the direct differentiation of embryonic stem
cells towards the
renal lineage by culturing the embryonic stem cells with retinoic acid,
activin A, BMP7 or BMP4
on laminin or gelatin substrates in a monolayer. They obtained cells with
upregulated
intermediate mesoderm marker genes (PAX2, SIX2, WT1 and OSR1) at day 4.
However,
markers for kidney precursors and markers of undifferentiated cells were also
elevated at day 4.
Batchelder et al do not show any further differentiation of this heterogeneous
population into
defined cell types. The differentiation of the embryonic stem cells is
achieved through a stage
with embryoid bodies, which generally limits reproducibility and
standardization of the protocol.
CA 02914479 2015-12-03
WO 2015/014731
PCT/EP2014/065991
-4-
Hence, prior art protocols for differentiation of human pluripotent stem cells
into kidney
percursors have major drawbacks: Firstly, most protocols result in a
heterogenous population of
cells and the absolute yield of defined renal precursor cells stably
expressing metanephric
mesenchyme markers is very low. In addition, the overall time needed to
differentiate pluripotent
stem cells into renal precursor cells by most known methods is very long. Many
protocols
require undefined elements such as medium conditioned with factors secreted by
primary cells,
co-cultures with feeder layers, which limit the standardization of these
methods. In addition,
many protocols rely on cell aggregates or embryoid bodies, which due to their
heterogeneous
nature constrain the reproducibility of these techniques.
Song et al. 2012 is the first reported protocol to differentiate human induced
pluripotent stem
cells into kidney podocytes. Following ten days of directed differentiation in
medium
supplemented with fetal bovine serum and different growth factors (BMP7,
Activin-A and
retinoic acid), the authors obtained iPS cells with a podocyte phenotype. They
obtained cells
expressing podocyte specific genes but also still expressing the metanephric
mesenchymal genes
PAX2 and WT1, indicating that the obtained podocytes are immature and not
fully differentiated.
Song et al do not describe any of the intermediate stages of the
differentiation like the
intermediate mesoderm or the metanephric mesenchyme.
None of the known protocols provide defined renal precursor cells that express
Six2, WT1, and
SALL1 with downregulation of the expression of PAX2, i.e. defined metanephric
mesenchyme
cells. None of the known protocols describe the differentiation of the renal
precursor cell into
podocytes.
In summary, there is no method that provides a defined population of renal
precursor cells
expressing metanephric mesenchyme markers at very high yield after only six
days. In addition
none of the known protocols provides fully functional and fully differentiated
podocytes at very
high yield after only 13 days.
The present invention provides an improved method for differentiating
pluripotent stem cells
into a defined metanephric mesenchyme renal precursor stage in a shorter
amount of time (6
days) and with a significantly increased yield (up to 95% yield of renal
precursor cells
expressing marker genes 5IX2, SALL1 and WT1) compared to prior art protocols.
The new
method alleviates the necessity of obtaining embryoid bodies or small cell
clumps from
pluripotent stem cells and removes the major drawback of low reproducibility
and
CA 02914479 2015-12-03
WO 2015/014731
PCT/EP2014/065991
-5-
standardization of methods known so far. Moreover, the high efficiency allows
the use of these
defined precursor cells in large scales in drug discovery and safety
assessments, in regenerative
medicine applications, and in in vitro disease modeling in the pharmaceutical
industry. In
addition, the new method permits the selective modulation of the metanephric
mesenchyme renal
precursor cells, which enables shifting lineage commitment into fully
differentiated podocytes
(-99%) after 13 days.
SUMMARY OF THE INVENTION
Provided herein is a method for differentiating pluripotent stem cells into
renal precursor
cells expressing SIX2, the method comprising the steps of:
a) providing a monolayer of pluripotent stem cells in a pluripotency medium
b) incubating the cells in a priming medium supplemented with a small molecule
inhibitor of
glycogen synthase kinase 3 (Gsk3a-b),
c) inducing the differentiation by incubating the primed cells in an induction
medium.
In one embodiment the renal precursor cells express the additional marker
genes WT1
and / or SALL1.
In one embodiment the small molecule inhibitor of glycogen synthase kinase 3
(Gsk3a-b)
is 3-(3-Amino-pheny1)-4-(1-methy1-1H-indo1-3-y1)-pyrrole-2,5-dione.
In one embodiment the pluripotency medium of step a) is a serum-free medium
supplemented with an inhibitor of the Rho-associated coiled-coil forming
protein
serine/threonine kinase family of protein kinases (ROCK kinase inhibitor).
In one embodiment the ROCK kinase inhibitor is selected from the group of 1-(5-
Isoquinolinesulfonyl) homopiperazine), N-Benzy1-2-(pyrimidin-4-ylamino)
thiazole-4-
carboxamide) and (+)-(R)-trans-4-(1-aminoethyl)-N-(4-pyridyl) cyclo-
hexanecarboxamide
dihydrochloride).
In one embodiment the priming medium of step b) is a serum free medium
supplemented
with insulin, transferrin and progesterone.
CA 02914479 2015-12-03
WO 2015/014731
PCT/EP2014/065991
-6-
In one embodiment the priming medium of step b) additionally comprises
recombinant
bone morphogenic protein-4 (BMP4).
In one embodiment step a) comprises incubating the cells in the pluripotency
medium for
18 hours to 30 hours.
In one embodiment step b) comprises incubating the cells in the priming medium
for 2 to
4 days.
In one embodiment step c) comprises incubating the cells in the induction
medium for 18
hours to 48 hours.
In one embodiment the induction medium is a serum-free medium supplemented
with
recombinant bone morphogenic protein-7 (BMP7).
In one embodiment the induction medium is a serum-free medium supplemented
with
Retinoic Acid.
In one embodiment the method additionally comprises step
d) incubating the product of step c) under conditions suitable for
proliferation of the podocytes.
In one embodiment the pluripotent stem cell is an induced pluripotent stem
cell.
In one embodiment the induced pluripotent stem cell is a human cell.
In one embodiment the induced pluripotent stem cell is obtained from a subject
suffering
from a renal disease.
In one embodiment renal precursor cells expressing SIX2 or differentiated
podocytes
obtained by a method according to any of the embodiments described herein is
provided.
In one embodiment a biobank of renal precursor cells expressing SIX2 or
differentiated
podocytes obtained by a method according to any of the embodiments described
herein is
provided.
In one embodiment use of renal precursor cells expressing SIX2 or
differentiated
podocytes obtained by a method according to any of the embodiments described
herein or of the
biobank of of renal precursor cells expressing SIX2 or differentiated
podocytes obtained by a
CA 02914479 2015-12-03
WO 2015/014731
PCT/EP2014/065991
-7-
method according to any of the embodiments described herein as in vitro model
for renal
diseases is provided.
In one embodiment a therapeutic composition comprising renal precursor cells
expressing
SIX2 or differentiated podocytes obtained by a method according to any of the
embodiments
described herein or of the biobank of of renal precursor cells expressing SIX2
or differentiated
podocytes obtained by a method according to any of the embodiments is
provided.
Any of the above embodiments may be present singly or in combination.
SHORT DESCRIPTION OF THE FIGURES
Figure 1: Quantification BRY+, PAX2+, LIM1+, iPSCs cells by image based high
content
analysis (HCA). Human iPS cells have been cultured in monolayer conditions.
Quantification graph:
Percent BRY+, PAX2+, and LIM1+ positive cells at Day 1 in pluripotency medium.
These findings
were confirmed by whole genome expression profiling (data not shown).
Figure 2: Quantification BRY+, PAX2+, LIM1+, iPSCs derived cells by image
based high
content analysis (HCA). Human iPS cells have been differentiated in monolayer
conditions.
Quantification graph: Percent BRY+, PAX2+, and LIM1+ positive cells at Day 4
in priming medium.
These findings were confirmed by whole genome expression profiling (data not
shown).
Figure 3: Quantification WT1+, SIX2+, SALL1+, and PAX2 low, iPSCs derived
multi-
competent renal precursors by image based high content analysis (HCA). Human
iPS cells have been
differentiated in monolayer conditions. Main panel: Quantification graph:
Percent WT1+, SIX2+,
SALL1+, and PAX2+ positive cells at Day 6 in induction medium. These findings
were confirmed
by whole genome expression profiling (data not shown).
Figure 4: Quantification WT1+, a-ACTININ4+, NEPRHIN+, PODOCIN+ and
SYNAPTOPODIN+, iPSCs derived functional Podocytes by image based high content
analysis
(HCA). Human iPS cells have been differentiated in monolayer conditions. Main
panel:
Quantification graph: Percent WT1+, a-ACTININ4+, NEPRHIN+, PODOCIN+ and
SYNAPTOPODIN+ positive cells at Day 13 in Podocytes proliferation medium.
These findings were
confirmed by whole genome expression profiling (data not shown).
Figure 5: Reproducibility of the Podocytes cell differentiation method using
as starting hESCs.
Image based high content analysis (HCA) quantification of key markers
regulated during the
CA 02914479 2015-12-03
WO 2015/014731
PCT/EP2014/065991
-8-
Podocytes cell differentiation method. The human embryonic stem cell line
(SA001 from Cellartis)
has been differentiated in monolayer conditions. Main panel: Quantification
graph: Percent PAX2+
positive cells at Day 4 in priming medium; SIX2+ and SALL1+ positive cells at
Day 6 in induction
medium; WT1+, and a-ACTININ4+ positive cells at Day 13 in Podocytes
proliferation medium.
Figure 6: Characterization of monolayer differentiated hPSCs-derived Podocytes
cells at Day
13. hiPSCs have been differentiated in monolayer conditions and at Day13 have
been tested for
functional response to TGF beta (10 ng/ml) stressor stimulation. The
expression of the tight junction
marker ZO-1 has been tested by immunocytochemistry analysis and its cellular
localization by image
based high content analysis (HCA). Upper panel: Representative images ZO-1
immunocytochemistry where it is show a defined ZO-1 localization at the
membrane for Day 1 in
DMEMF12 Medium without TGF Beta (CTR D1 ¨ TGEb1), upon TGF beta stimulation we
report a
remodeling and translocation of the ZO-1 expression form the membrane to the
perinuclear zone
already at Day 1 (D1 + TGEb1), and it is sustained over time by the continuous
stimulation with TGF
beta (D2 + TGEbl and (D5 + TGEb1). Lower panel: Quantification graph: Percent
positive cells for
perinuclear translocation of ZO-1 expression in podocytes at different days.
Figure 7: Characterization of monolayer differentiated hPSCs-derived Podocytes
cells at Day
13. hiPSCs have been differentiated in monolayer conditions and at Day13 have
been tested for
functional response to Angiotensin II (AngII) (100 nM) stressor stimulation.
The expression of the
tight junction marker ZO-1 has been tested by immunocytochemistry analysis and
its cellular
localization by image based high content analysis (HCA). Upper panel:
Representative images ZO-1
immunocytochemistry where it is show a defined ZO-1 localization at the
membrane for Day 1 in
DMEMF12 Medium without AngII (CTR D1 ¨ AngII), upon AngII stimulation we
report a
remodeling and translocation of the ZO-1 expression form the membrane to the
perinuclear zone
already at Day 1 (D1 + AngII), and it is sustained over time by the continuous
stimulation with AngII
(D2 + AngII and (D5 + AngII). Lower panel: Quantification graph: Percent
positive cells for
perinuclear translocation of ZO-1 expression in podocytes at different days.
Figure 8: Pro-inflammatory cytokine response assay. hPSCs-derived Podocytes
cells at Day
13 upregulate the expression of pro-inflammatory markers such as IL-8 ,
RANTES, MIP lb and
MCP1 upon stimulation with TNFa (lng/m1 and 5 ng/ml) after 24h in DMEMF12
medium Main
panel: Quantification graph: concentration in the harvested supernatant
(pg/ml) of the mentioned
cytokines. Bio-Plex Pro Cytokine, Chemokine and Growth factor assay was used
to measure the
activation of hPSCs-derived Podocytes cells in response to TNFa. The secreted
cytokines were
significantly upregulated (quantification graphs).
CA 02914479 2015-12-03
WO 2015/014731
PCT/EP2014/065991
-9-
Figure 9: Schematic representation of the method for differentiating human
pluripotent stem
cells (PSCs) to Podocytes. Day 0: human PSCs were enzymatically dissociated
and plated on pre-
coated matrigel plates using a concentration of 37000 cells/em2in pluripoteney
medium (mTeSR1
with Y27631 10 pM). Day 1: Media change with fresh priming medium (N2B27 with
Compound 21
(CP21R7) 1 pM and 25 ng/ml BMP4). Day 4: Media change with fresh induction
medium
(DMEMF12 with 2.5% FBS, 100 nM Retinoic Acid and 50 ng/ml BMP7).Day 6: The
cells are
detached with accutase and after centrifugation plated in collagen I coated
plates using a
concentration of 50000 cells/em2 in Podocytes proliferation medium (DMEMF12
with 10% FBS, 0.1
mM Retinoic Acid and 100 nM Vitamin D3). At Day 13 Podocytes cells are shown.
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides an improved method for differentiating
pluripotent stem cells
into a defined metanephric mesenchyme renal precursor stage in a shorter
amount of time (6
days) and with a significantly increased yield (up to 95% yield of renal
precursor cells
expressing marker genes SIX2, SALL1 and WT1) compared to prior art protocols.
The renal
precursor cells express SIX2, SALL1 and WT1, which are all important markers
of the
metanephric mesenchyme. SIX2, also known as SIX homeobox 2 (NCBI Gene ID:
10736), is a
member of the vertebrate gene family which encode proteins homologous to the
Drosophila 'sine
oculis' homeobox protein. The encoded protein is a transcription factor which
has an important
role for metanephros development. 5IX2 is an important marker of the
metanephric mesenchyme
(see e.g. Nishinakamura et al, 2011 and Chai et al, 2013). SALL1 (full name:
SALL1 sal-like 1
(Drosophila) [Homo sapiens (human)] NCBI Gene ID: 6299), is also known as TBS;
HSALl;
Sal-1; ZNF794. The protein encoded by this gene is a zinc finger
transcriptional repressor and is
highly expressed in multipotent nephron progenitors in the mesenchyme
(Nishinakamura et al,
2011). WT1 (full name: Wilms tumor 1, also known as GUD; AWT1; WAGR; WT33;
NPHS4;
WIT-2; EWS-WT, NCBI Gene ID:7490) encodes a transcription factor that contains
four zinc-
finger motifs at the C-terminus and a proline/glutamine-rich DNA-binding
domain at the N-
terminus. It has an essential role in the normal development of the urogenital
system, and it is
mutated in a small subset of patients with Wilm's tumors. WT1 is an important
marker of the
metanephric mesenchyme (see e.g. Chai et al, 2013).
CA 02914479 2015-12-03
WO 2015/014731
PCT/EP2014/065991
-10-
In addition to obtaining defined metanephric mesenchyme renal precursor cells,
the new method
permits the selective modulation of the metanephric mesenchyme renal precursor
cells, which
enables shifting lineage commitment into fully differentiated podocytes (-99%)
after 13 days.
Provided herein is a method for differentiating pluripotent stem cells into
renal precursor cells
expressing SIX2, the method comprising the steps of:
a) providing a monolayer of pluripotent stem cells in a pluripotency medium
b) incubating the cells in a priming medium supplemented with a small molecule
inhibitor of
glycogen synthase kinase 3 (Gsk3a-b),
c) inducing the differentiation by incubating the primed cells in an induction
medium.
In one embodiment the renal precursor cells are metanephric mesenchyme cells.
In one
embodiment the renal precursor cells express the additional marker genes WT1
and / or SALL1.
In one embodiment the renal precursor cells express WT1, SALL1 and SIX2. In
another
embodiment the renal precursor cells downregulate marker genes of the
intermediate mesoderm.
Hence, in one embodiment the renal precursor cell express PAX2 only at a very
low level. PAX2
(full name Paired Box 2, NCBI Gene ID 5076, also known as PAPRS) encodes
paired box gene
2, one of many human homologues of the Drosophila melanogaster gene prd. The
central feature
of this transcription factor gene family is the conserved DNA-binding paired
box domain. PAX2
is an important marker of the intermediate mesoderm (Chai et al, 2013,
Nishikawa et al, 2012)
and is downregulated in the metanephric mesenchyme. In one embodiment the
renal precursor
cells do not express LIM1 and/ or BRY. LIM1 (official symbol LHX1, full name
LIM homeobox
1, NCBI Gene ID 3975) encodes a member of a large protein family which
contains the LIM
domain, a unique cysteine-rich zinc-binding domain. The encoded protein is a
transcription
factor important for the development of the renal and urogenital systems: LIM1
is a marker for
nephrogenic intermediate mesoderm (Nishikawa et al, 2012). The protein product
of the T gene
(full name: T, brachyury homolog (mouse) [Homo sapiens (human)] NCBI Gene ID:
6862,
herein referred to as "BRY"), Brachyury, is an embryonic nuclear transcription
factor and widely
used as the definitive benchmark for mesodermal differentiation (Nishikawa et
al, 2012).
Preferably the media are changed in between each steps, that means that the
first medium is
discarded e.g. by aspiration before the second medium is added to the cells.
"A monolayer of pluripotent cells" as used herein means that the pluripotent
stem cells are
provided in single cells which are attached to the adhesive substrate in one
single film, as
CA 02914479 2015-12-03
WO 2015/014731
PCT/EP2014/065991
-11-
opposed to culturing cell clumps or embryoid bodies in which a solid mass of
cells in multiple
layers form various three dimensional formations attached to the adhesive
substrate.
Providing a monolayer of pluripotent stem cells in the initial step is crucial
for the
reproducibility and efficiency of the method. In one embodiment, monolayers of
pluripotent
stem cells can be produced by enzymatically dissociating the cells into single
cells and bringing
them onto an adhesive substrate, such as pre-coated matrigel plates (e.g. BD
Matrigel hESC-
qualified from BD Bioscience, Geltrex hESC-qualified from Invitrogen,
Synthemax from
Corning).
Examples of enzymes suitable for the dissociation into single cells include
Accutase (Invitrogen),
Trypsin 25 (Invitrogen), TrypLe Express (Invitrogen). In one embodiment, 20000
to 60000 cells
per cm2 are plated on the adhesive substrate. The medium used herein is a
pluripotency medium
which facilitates the attachment and growth of the pluripotent stem cells as
single cells in a
monolayer.
"Pluripotency medium" as used herein refers to any chemically defined medium
useful for the
attachment of the pluripotent stem cells as single cells on a monolayer while
maintaining their
pluripotency and are well known in the art. In one embodiment the pluripotency
medium
comprises at least one of the following growth factors: basic fibroblast
growth factor (bFGF, also
depicted as Fibroblast Growth Factor 2, FGF2) and transforming growth factor 0
(TGFI3). In one
embodiment, the pluripotency medium is a serum free medium supplemented with a
small
molecule inhibitor of the Rho-associated coiled-coil forming protein
serine/threonine kinase
(ROCK) family of protein kinases (herein referred to as ROCK kinase
inhibitor).
Thus, in one embodiment, step a) of the method described above comprises
providing a
monolayer of pluripotent stem cells in a pluripotency medium, wherein the
pluripotency medium
is a serum free medium supplemented with a ROCK kinase inhibitor.
Examples of serum-free pluripotency media suitable for the attachment are
mTeSR1 or TeSR2
from Stem Cell Technologies, Primate ES/IFS cell medium from ReproCELL and
StemPro
hESC SFM from Invitrogen, X-VIVO from Lonza, Stemline Pluripotent Stem Cell
Culture
Medium from Sigma Aldrich, NutriStem XF/FF Culture Medium from Stemgent,
Essential 8TM
Medium (prototype) from Invitrogen and STEMium from ScienCell Research
Laboratories.
CA 02914479 2015-12-03
WO 2015/014731
PCT/EP2014/065991
-12-
Examples of ROCK kinase inhibitor useful herein are Fasudil (1-(5-
Isoquinolinesulfonyl)homopiperazine), Thiazovivin (N-Benzy1-2-(pyrimidin-4-10
ylamino)thiazole-4-carboxamide) and Y27632 ((+)-(R)-trans-4-(1-aminoethyl)-N-
(4-pyridyl)
cyclo-hexanecarboxamide dihydrochloride, e.g. Catalogue Number: 1254 from
Tocris
bioscience). In one preferred embodiment the ROCK kinase inhibitor is Y27632.
In one
embodiment, the pluripotency medium is a serum free medium supplemented with 2-
20 [tIVI
Y27632, preferably 5-10 [tIVI Y27632. In another embodiment the pluripotency
medium is a
serum free medium supplemented with 2-20 [tIVI Fasudil. In another embodiment
the
pluripotency medium is a serum free medium supplemented with 0.2-10 [tIVI
Thiazovivin.
In one embodiment step a) of the method described above comprises providing a
monolayer of
pluripotent stem cells in a pluripotency medium and incubating (growing) the
monolayer in the
pluripotency medium for one day (24 hours). In another embodiment step a) of
the method
described above comprises providing a monolayer of pluripotent stem cells in a
pluripotency
medium and incubating the monolayer in the pluripotency medium for 18 hours to
30 hours,
preferably for 23 to 25 hours.
In another embodiment step a) of the method described above comprises
providing a monolayer
of pluripotent stem cells in a pluripotency medium, wherein the pluripotency
medium is a serum-
free medium supplemented with a ROCK kinase inhibitor, and incubating the
monolayer in the
pluripotency medium for one day (24 hours). In another embodiment step a) of
the method
described above comprises providing a monolayer of pluripotent stem cells in a
pluripotency
medium, wherein the pluripotency medium is a serum-free medium supplemented
with a ROCK
kinase inhibitor, and incubating the monolayer in the pluripotency medium for
18 hours to 30
hours, preferably for 23 to 25 hours.
A "suitable medium for priming", also depicted as "priming medium", as used
herein refers to
any chemically defined medium useful for priming of the pluripotent stem cells
towards renal
precursor cells. As used herein, "priming medium" refers to a medium that
comprises at least one
factor, such as a small molecule that activates the Beta-Catenin (cadherin-
associated protein,
beta 1; human gene name CTNNB1) pathway and/or the Wnt receptor signaling
pathway and/or
hedgehog (HH) signaling pathway, that promotes the induction activity of
intermediate
mesoderm. In one preferred embodiment the priming medium comprises a small
molecule
inhibitor of glycogen synthase kinase 3 (Gsk3a-b). In one embodiment the a
small molecule
CA 02914479 2015-12-03
WO 2015/014731
PCT/EP2014/065991
-13-
inhibitor of glycogen synthase kinase 3 (Gsk3a-b) is 3-(3-Amino-pheny1)-4-(1-
methy1-1H-indol-
3-y1)-pyrrole-2,5-dione.
Upon incubation in priming medium, the pluripotent stem cells start to change
cell morphology
overtime and the cell proliferation is increased. The "priming" step is
defined by the expression
of specific genes and markers involved into the intermediate mesoderm
transition (e.g.
upregulation of BRY, PAX2, LIM1, GATA2, VIMENTIN, SMA, HAND1, KDR and FOXa2
(low expression)) and down regulation of the pluripotency associated genes and
markers (e.g.
OCT4 (POU5F1), NANOG, SOX2, REX1 (ZFP42), LEFTY1, LEFTY2, TDGF1, DNMT3B,
GABRB3, GDF3, TERT, see e.g. Tan et al, 2007).
In one embodiment the small molecules activating Beta-Catenin (cadherin-
associated protein,
beta 1; human gene name CTNNB1) pathway and/or the Wnt receptor signaling
pathway and/or
hedgehog (HH) signaling pathway are selected from the group consisting of
small molecule
inhibitors of glycogen synthase kinase 3 (Gsk3a-b), small molecule inhibitors
of CDC-like
kinase 1 (C1k1-2-4), small molecule inhibitors of mitogen-activated protein
kinase 15 (Mapk15),
small molecule inhibitors of dual-specificity tyrosine-(Y)-phosphorylation
regulated kinase
(Dyrkla-b 4), small molecule inhibitors of cyclin-dependent kinase 16 (Pctk1-3
4), Smoothened
(SMO) activators and modulators of the interaction between13-catenin (or y-
catenin) 15 and the
coactivator proteins CBP (CREB binding protein) and p300 (ElA binding protein
p300).
Preferably the glycogen synthase kinase 3 (Gsk3a-b) inhibitors are
pyrrolidindione-based GSK3
inhibitors. "Pyrrolidindione-based GSK3 inhibitor" as used herein relates to
selective cell
permeable ATP-competitive inhibitors of GSK3a and GSK3I3 with low IC50 values.
In one
embodiment the pyrrolidindione-based GSK3 inhibitor is selected from the group
comprising 3-
(2,4-Dichloropheny1)-4-(1-methy1-1H-indo1-3-y1)-1H-pyrrole-2,5-dione
(SB216763), 3-[(3-
Chloro-4-hydroxyphenyl)amino]-4-(2-nitropheny1)-1H-pyrro1-2,5-dione
(SB415286), N6- {2-[4-
(2,4-Dichloro-phenyl)-5-imidazol-1-yl-pyrimidin-2-ylamino]-ethyl-3-nitro-
pyridine-2,6-diamine
2HC1, 3-Imidazo[1,2-a]pyridin-3-y1-4-[2-(morpholine-4-carbony1)-25 1,2,3,4-
tetrahydro-
[1,4]diazepino[6,7,1-hi]indo1-7-y1]-pyrrole-2,5-dione, 9-Bromo-7,12-dihydro-
indolo[3,2-
d][1]benzazepin-6(5H)-one (Kenpaullone), 9-Bromo-7,12-dihydro-pyrido [3 - ,2 -
:2,3] azepino
[4,5-b]indo1-6(5H)-one (CHIR99021) and (3-(3-Amino-pheny1)-4-(1-methy1-1H-
indo1-3-y1)-
pyrrole-2,5-dione (CP21R7, also referred to as "compound 21" herein; see e.g.
L. Gong et al;
Bioorganic& Medicinal Chemistry Letters 20 (2010), 1693-1696). In one
embodiment the CDC-
like kinase 1 (C1k1-2-4) inhibitor is selected from the group comprising
benzothiazole and 3-
CA 02914479 2015-12-03
WO 2015/014731
PCT/EP2014/065991
-14-
Fluoro-N-[1-isopropy1-6-(1-methyl-piperidin-4-yloxy)-1,3-dihydro-benzoimidazol-
(2E)-
ylidene]-5-(4-methy1-1H-pyrazole-3-sulfony1)-benzamide. In one embodiment the
mitogen-
activated protein kinase 15 (Mapk15) inhibitor is selected from the group
comprising 4-(4-
Fluoropheny1)-2-(4-methylsulfinylpheny1)-5-(4-pyridy1)-1H-imidazole (SB203580)
and, 5-
Isoquinolinesulfonamide (H-89).
In one embodiment the dual-specificity tyrosine-(Y)-phosphorylation regulated
kinase 5
(Dyrkla-b 4) inhibitor is selected from the group comprising 6-[2-Amino-4-oxo-
4H-thiazol-
(5Z)-ylidenemethy1]-4-(tetrahydro-pyran-4-yloxy)-quinoline-3-carbonitrile.
In one embodiment the smoothened activator is Purmorphamine (2-(1-Naphthoxy)-6-
(4-
morpholinoanilino)-9-cyclohexylpurine. Examples of modulators of the
interaction between f3-
catenin (or y-catenin) and the coactivator proteins CBP (CREB binding protein)
and p300 (ElA
binding protein p300) are IQ-1 (2-(4-Acetyl-phenylazo)-2-[3,3-dimethy1-3,4-
dihydro-2H-
isoquinolin-(1E)-ylidene]-acetamide, and ICG-001((6S,9aS)-6-(4-Hydroxy-benzy1)-
8-
naphthalen-1-ylmethy1-4,7-dioxo-hexahydro-15 pyrazino[1,2-a]pyrimidine-l-
carboxylic acid
benzylamide (WO 2007056593).
In one embodiment the priming medium is a serum free medium supplemented with
insulin, transferrin and progesterone. In one embodiment the serum free medium
is
supplemented with 10-50 [tg/ ml insulin, 10-100 pg/ ml transferrin and 10-50
nM progesterone,
preferably 30-50 [tg/ ml insulin, 20-50 [tg/ ml transferrin and 10-30 nM
progesterone. Examples
of serum-free media suitable for priming are N2B27 medium (N2B27 is a 1:1
mixture of
DMEM/F12 (Gibco, Paisley, UK) supplemented with N2 and B27 (both from Gibco)),
N3
medium (composed of DMEM/F12 (Gibco, Paisley, UK), 25 [tg/ ml insulin, 50 [tg/
ml
transferrin, 30 nM sodium selenite, 20 nM progesterone, 100 nM putrescine
(Sigma)), or 25
NeuroCult0 NS-A Proliferation medium (Stemcell Technologies). In one
embodiment the
priming medium is a serum free medium supplemented with insulin, transferrin,
progesterone
and a small molecule inhibitor of glycogen synthase kinase 3 (Gsk3a-b).
Preferably the small molecule inhibitor is (3-(3-Amino-pheny1)-4-(1-methy1-1H-
indo1-3-
y1)-pyrrole-2,5-dione, also referred to as CP21R7 therein. In one embodiment
the priming
medium is a serum- free medium comprising 10-50 [tg/ ml insulin, 10-100 [tg/
ml transferrin and
10-50 nM progesterone and 0.5-4 [iM CP21R7 (3-(3-Amino-pheny1)-4-(1-methy1-1H-
indo1-3-
y1)-pyrrole-2,5-dione). In one such embodiment the priming medium comprises 1
[iM CP21R7.
CA 02914479 2015-12-03
WO 2015/014731
PCT/EP2014/065991
-15-
In one embodiment the priming medium of any of the embodiments described
herein
additionally comprises recombinant bone morphogenic protein-4 (BMP4). In one
preferred
embodiment the priming medium is a serum- free medium comprising 10-50 ug/ ml
insulin, 10-
100 ug/ ml transferrin,10-50 nM progesterone, 0.5-4 uM CP21R7 (3-(3-Amino-
phenyl)-4-(i-
methyl-1H-indo1-3-y1)-pyrrole-2,5-dione) and 10-50 ng/ ml recombinant bone
morphogenic
protein-4 (BMP4).
In one embodiment step b) of the method described above comprises incubating
the cells
in a priming medium for at least 3 days (72 hours). In one embodiment step b)
of the method
described above comprises incubating the cells in a priming medium for 2 to 4
days (48 hours to
96 hours). In another embodiment step b) of the method described above
comprises incubating
the cells in a priming medium, wherein the priming medium is a serum-free
medium
supplemented with CP21R7 (3-(3-Amino-pheny1)-4-(1-methy1-1H-indo1-3-y1)-
pyrrole-2,5-
dione). Preferably the priming medium is supplemented with 0.5 ¨ 4 uM CP21R7
(3-(3-Amino-
pheny1)-4-(1-30 methyl-1H-indo1-3-y1)-pyrrole-2,5-dione), most preferably 1-2
uM CP21R7 (3-
(3-Amino-pheny1)-4-(1-methy1-1H-indo1-3-y1)-pyrrole-2,5-dione). In one
embodiment the
priming medium additionally comprises recombinant bone morphogenic protein-4
(BMP4). In
another embodiment step b) of the method described above comprises incubating
the cells in a
priming medium, wherein the priming medium is a serum-free medium supplemented
with
CP21R7 (3-(3-Amino-pheny1)-4-(1-methy1-1H-indo1-3-y1)-pyrrole-2,5-dione), and
incubating
the cells for three days (72 hours). In one such embodiment the priming medium
additionally
comprises recombinant bone morphogenic protein-4 (BMP4).
In another embodiment step b) of the method described above comprises
incubating the cells in a
priming medium, wherein the priming medium is a serum-free medium supplemented
with
CP21R7 (3-(3-Amino-pheny1)-4-(1-methy1-1H-indo1-3-y1)-pyrrole-2,5-dione), and
incubating
the cells for 2 to 4 days (48 hours to 96 hours). In one such embodiment the
priming medium
additionally comprises recombinant bone morphogenic protein-4 (BMP4).
"Induction medium" as used herein refers to any chemically defined medium
useful for the
induction of primed cells into SIX2 and/or WT1 and/or SALL1 positive renal
precursor cells on
a monolayer. In one embodiment the renal precursor cells express all three
marker genes SIX2,
WT1 and SALL1 and are referred to as SWS+ renal precursor cells. In one
embodiment the renal
precursor cells are metanephric mesenchyme cells. In another embodiment the
renal precursor
cells downregulate marker genes of the intermediate mesoderm. Hence, in one
embodiment the
CA 02914479 2015-12-03
WO 2015/014731
PCT/EP2014/065991
-16-
renal precursor cell express PAX2 only at a very low level. In one embodiment
the renal
precursor cells do not express LIM1 and/ or BRY.
Examples of media suitable for the induction are DEMEM/F12, RPMI 1640
(Invitrogen) or
William's E Medium (Invitrogen).
In one embodiment the induction medium is supplemented with a Bone morpho
genetic protein
(BMP), like BMP4, BMP7 or other BMPs like BMP2, BMP3, BMP 5, BMP 6, BMP 8a,
BMP
8b, or BMP 9.
Preferably the induction medium is a medium supplemented with BMP7. In one
such
embodiment the induction medium is supplemented with 20 ¨ 80 ng/ml BMP7,
preferably 50
ng/ml BMP7.
With the new method presented herein it is now possible to differentiate renal
precursor cells
expressing SIX2 from pluripotent stem cells with a yield of up to 95 %. The
product of step c)
can be easily identified in a cell culture as SIX2 and WT1 and/or SALL1
positive cells.
In one embodiment the induction medium additionally comprises Retinoic acid
(RA), like all-
trans- Retinoic acid or 9-cis Retinoic acid. In another embodiment the
induction medium
comprises a Retinoic Acid inhibitor or an Retinoic Acid agonist. Retinoic acid
inhibitors and
Retinoic acid agonists are well known in the art.
Preferably the induction medium is a medium supplemented with RA. In one such
embodiment
the induction medium is supplemented with 50-200 nM RA, preferably 100 nM RA.
In one embodiment the induction medium is supplemented with RA and BMP7.
In one embodiment the induction medium additionally comprises 1- 5% serum,
preferably 2.5%
serum. Serum useful therein is for example fetal bovine serum, known in the
art. In another
embodiment the induction medium is supplemented with amino acids, e.g. non
essential
Aminoacid solution from Sigma- Aldrich (Catalogue number M7145).
In another embodiment the induction medium additionally comprises beta-
mecaptoethanol.
In one embodiment step c) of the method described above comprises incubating
the cells in a
induction medium for 2 days (48 hours).
CA 02914479 2015-12-03
WO 2015/014731
PCT/EP2014/065991
-17-
In one embodiment, steps a) to c) of the method described above together take
six days.
In embodiment the method as described in any the above embodiments is useful
for
differentiating pluripotent stem cells into podocytes. In one embodiment the
method as described
in any of the above embodiments additionally comprises step
d) incubating the product of step c) under conditions suitable for
proliferation of podocytes.
Typically, the SWS+ cells obtained in step c) are harvested and expanded in a
chemically
defined proliferation medium. In one embodiment, step d) comprises incubating
the cells
obtained in step c) for 24-168h, preferably for 48-96 hours in a proliferation
medium.
Proliferation medium as used herein is a medium supplemented with growth
factors and/or
small molecules enhancing the proliferation and survival of podocytes cells.
In one embodiment step the proliferation medium is a chemically supplemented
medium (SP
medium). SP media useful herein are e.g. DMEM/F12 medium (e.g. Invitrogen or
Gibco Cat
num. 31331-028) or RPMI 1640 (Gibco Cat num. 61870-010) or DMEM medium). In
one
embodiment the proliferation medium is supplemented with 2-10 % serum, for
example 2-10%
fetal bovine serum. In one embodiment the proliferation medium is supplemented
with a Knock-
out serum replacement (e.g. from Invitrogen, Catalogue number 10828028).
In another embodiment the proliferation medium is supplemented with 0.1-0.5 mM
RA,
preferably 0.1mM RA. In another embodiment the proliferation medium is
supplemented with
10-200 nM Vitamin D3, preferably 100 nM Vitamin D3. In one embodiment the
proliferation
medium is supplemented with both RA and Vitamin D3. In one embodiment the
proliferation
medium further comprises stable glutamine. In a preferred embodiment the
proliferation medium
is a DMEM/F12 medium supplemented with 10% serum, 100 nM Vitamin D3 and 0.1mM
Retinoic Acid.
The renal precursor cells and podocytes obtained by the method described
herein can be
expanded for several passages.
Any of the above embodiments may be present singly or in combination.
In one embodiment of the present invention a method for generating patient
specific or
healthy individual specific renal precursor cells or podocytes is provided.
Towards this end,
human induced pluripotent stem cells (iPSCs) obtained from a patient or
healthy individual are
differentiated into renal precursor cells or podocytes with the method
described herein. The
CA 02914479 2015-12-03
WO 2015/014731
PCT/EP2014/065991
-18-
patient-specific human iPSCs can be obtained by methods known in the art by
reprogramming
somatic cells obtained from the patients or healthy individuals to pluripotent
stem cells. For
example, fibroblast cells, keratinocytes or adipocytes may be obtained by skin
biopsy from the
individual in need of treatment or from a healthy individual and reprogrammed
to induced
pluripotent stem cells by the methods known in the art. Other somatic cells
suitable as a source
for induced pluripotent stem cells are leucocytes cells obtained from blood
samples or epithelial
cells or other cells obtained from urine samples. The patient specific induced
pluripotent stem
cells are then differentiated to patient specific or healthy individual
specific renal precursor cells
or podocytes by the method described herein. In another aspect of the
invention, a population of
renal precursor cells or podocytes produced by any of the foregoing methods is
provided.
Preferably, the population of renal precursor cells or podocytes is patient
specific, i.e. derived
from iPSCs obtained from diseased individuals. In another embodiment the
population of renal
precursor cells or podocytes is obtained from a healthy individual.
Patient derived renal precursor cell or podocytes represent a disease relevant
in vitro model
to study the pathophysio logy of renal diseases like acute kidney
failure/acute kidney injury,
Alport syndrome, angiotensin antibodies and focal segmental
glomerulosclerosis, APOL1
mutations, CFHR5 nephropathy, Bartter syndrome, collapsing glomerulopathy,
diabetes and
diabetic kidney disease related to CMV, Fabry's disease, glomerular diseases,
HIV-associated
nephropathy (HIVAN), lipoprotein glomerulopathy, lupus kidney disease, lupus
nephritis,
membranoproliferative glomerulonephritis, nodular glomerulosclerosis, post-
infectious
glomerulonephritis, post-streptococcal glomerulonephritis. In one embodiment
the renal
precursor cells or podocytes obtained by this method are used for screening
for compounds that
reverse, inhibit or prevent renal diseases caused by dysfunction of renal
cells, e.g. Chronic
Kidney Disease (CKD), Focal segmental glomerulosclerosis (FSGS),
Membranoproliferative
glomerulonephritis, Polycystic kidney disease (PKD) and diabetic nephropathy
associated with
Diabetes Type-2. Preferably, the renal precursor cells or podocytes obtained
by the method of
the invention described herein are derived from diseased subjects. In another
embodiment the
renal precursor cells or podocytes obtained by this method are used for
screening and evaluating
new targets and compounds for treatment of Diabetes and Diabetic Kidney
Disease. Preferably,
the renal precursor cells or podocytes obtained by the method of the invention
described herein
are derived from individuals affected by renal diseases like for example
Chronic Kidney Disease
(CKD), Focal segmental glomerulosclerosis (FSGS), Membranoproliferative
glomerulonephritis,
Polycystic kidney disease (PKD) and diabetic nephropathy associated with
Diabetes Type-2.
Differentiating renal precursor cells and/ or podocytes from diseased subjects
represents a unique
opportunity to early evaluate drug safety in a human background paradigm. In
another
embodiment the podocytes obtained by this method are used as an in vitro model
of the nephron.
CA 02914479 2015-12-03
WO 2015/014731
PCT/EP2014/065991
-19-
The present invention provides a highly efficient method to supply patient
specific
podocytes or compatible cells from healthy individuals with the same HLA type
suitable for
transplantation, both derived in xeno-free conditions. "Xeno-free culture
conditions" refers to a
medium and a substrate for attachment that comprising components only of human
and
recombinant origin. Thus the risk of contamination with xenopathogens is
circumvented and the
renal cells are safe for use in regenerative medicine. Differentiation of
patient specific induced
pluripotent stem cells (iPSCs) into patient specific podocytes with the method
described herein
represents an easy accessible and reproducible technology to generate
autologous sources of
podocytes. The use of autologous and/or compatible cells in cell therapy
offers a major
advantage over the use of non-autologous cells, which are likely to be subject
to immunological
rejection. In contrast, autologous cells are unlikely to elicit significant
immunological responses.
In a further preferred aspect of the invention the generation of a BioBank of
patient
specific renal precursor cells or podocytes is envisaged. In one embodiment, a
BioBank
comprising different populations of renal precursor cells or podocytes
obtained from healthy
individuals and / or patients is generated. The term "BioBank" as used herein
means a library of
biological samples taken from different individuals or species. The archived
collection of
specimen and associated data is intended for research purposes with the aim of
addressing
diseases associated with vascular complications. In another embodiment, the
BioBank is used for
vascular regenerative medicine approaches.
In another aspect, the invention provides a therapeutic composition comprising
renal
precursor cells or podocytes produced by any of the foregoing methods or
comprising any of the
foregoing cell populations. Preferably, the therapeutic compositions further
comprise a
physiologically compatible solution including, for example, a phosphate-
buffered saline with 5%
human serum albumin. The therapeutic composition can be used to treat,
prevent, or stabilize
renal diseases such as for example, Chronic Kidney Disease (CKD), Focal
segmental
glomerulosclerosis (FSGS), Membranoproliferative glomerulonephritis,
Polycystic kidney
disease (PKD) and diabetic nephropathy associated with Diabetes Type-2. For
example,
fibroblast cells, keratinocytes or adipocytes may be obtained by skin biopsy
from the individual
in need of treatment or from a healthy individual and reprogrammed to induced
pluripotent stem
cells by the methods known in the art ("Induction of pluripotent stem cells
from adult human
fibroblasts by defined factors." Takahashi et al., 2007, Cell 131, 861-72).
Other somatic cells
suitable as a source for induced pluripotent stem cells are leucocytes cells
obtained from blood
samples or epithelial cells or other cells obtained from urine samples. The
patient specific
induced pluripotent stem cells are then differentiated to podocytes by the
method described
herein, harvested and introduced into the individual to treat the condition.
The renal precursor
cells or podocytes produced by the method of the invention may be used to
replace or assist the
normal function of diseased or damaged tissue.
CA 02914479 2015-12-03
WO 2015/014731
PCT/EP2014/065991
-20-
Another embodiment of the invention is the use of BioBanks of renal precursor
cells or
podocytes for therapy of renal diseases. The BioBanks preferably comprise
renal precursor cells
or podocytes obtained from patients or healthy individuals with several HLA
types.
Transplanting cells obtained from a healthy donor to an individual in need of
treatment with a
compatible HLA type obviates the significant problem of rejection reactions
normally associated
with heterologous cell transplants. Conventionally, rejection is prevented or
reduced by the
administration of immunosuppressants or anti-rejection drugs such as
cyclosporine. However,
such drugs have significant adverse side-effects, e.g., immunosuppression,
carcinogenic
properties, kidney toxicity as well as being very expensive. The present
invention eliminates, or
at least significantly reduces, the need for anti-rejection drugs, such as
cyclosporine, imulan, FK-
506, glucocorticoids, and rapamycin, and derivatives thereof.
With respect to the therapeutic methods of the invention, it is not intended
that the
administration of renal precursor cells or podocytes to a mammal be limited to
a particular mode
of administration, dosage, or frequency of dosing; the present invention
contemplates all modes
of administration, including intramuscular, intravenous, intrarticular,
intralesional, subcutaneous,
or any other route sufficient to provide a dose adequate to prevent or treat a
disease. The renal
precursor cells or podocytes may be administered to the mammal in a single
dose or multiple
doses. When multiple doses are administered, the doses may be separated from
one another by,
for example, one week, one month, one year, or ten years. One or more growth
factors,
hormones, interleukins, cytokines, small molecules or other cells may also be
administered
before, during, or after administration of the cells to further bias them
towards a particular cell
type.
As used herein the term "differentiating", "differentiation" refers to one or
more steps to
convert a less-differentiated cell into a somatic cell, for example to convert
a pluripotent stem
cell into renal precursor cells or podocytes. Differentiation of a pluripotent
stem cell to renal
precursor cells or podocytes is achieved by the method described herein.
The term "stem cell" as used herein refers to a cell that has the ability for
self-renewal. An
"undifferentiated stem cell" as used herein refers to a stem cell that has the
ability to differentiate
into a diverse range of cell types. As used herein, "pluripotent stem cells"
as used herein refers to
a stem cell that can give rise to cells of multiple cell types. Pluripotent
stem cells (PSCs) include
human embryonic stem cells (hESCs) and human induced pluripotent stem cells
(hiPSCs).
Human induced pluripotent stem cells can be derived from reprogrammed somatic
cells, e.g. by
transduction of four defined factors (Sox2, Oct4, K1f4, c-Myc) by methods
known in the art. The
human somatic cells can be obtained from a healthy individual or from a
patient. These donor
cells can be easily obtained from any suitable source. Preferred herein are
sources that allow
CA 02914479 2015-12-03
WO 2015/014731
PCT/EP2014/065991
-21-
isolation of donor cells without invasive procedures on the human body, for
example human skin
cells, blood cells or cells obtainable from urine samples. Although human
pluripotent stem cells
are preferred, the method is also applicable to non-human pluripotent stem
cells, such as primate,
rodent (e.g. rat, mouse, rabbit) and dog pluripotent stem cells.
As used herein, "renal precursor cells" or "cells in a metanephric mesenchyme
renal precursor
stage" are cells that differentiated into the metanephric mesenchyme stage and
express at least
the cellular marker SIX2, and in a preferred embodiment also the cellular
markers SALL1 and
WT1. Renal precursor cells as used herein are characterized by down-regulation
of marker genes
of the pluripotent stage and the intermediate mesoderm stage, like for example
PAX 2, BRY and/
or LIM1 . These cells have the potential to differentiate into all renal
cells, including the ability
to give rise to podocytes.
As used herein "intermediate mesoderm cells" are cells that express one or
more of the
cellular markers BRY, LIM1 and PAX2 and which do not express SIX2, SALL1 and
WT1, or
only at a very low level.
As used herein "downregulation of a marker" refers to a decrease of an
expression level of
a marker gene and its gene product. The term can mean that the expression
level of a certain
marker gene and its gene product in one differentiation stage is decreased
compared to another
differentiation stage. "Downregulation of a marker" can also refer to a
complete abolishment of
the expression of a marker gene and its gene product in a cell, e.g. the
expression of the marker
gene and its gene product is not detectable any more.
As used herein "upregulation of a marker" refers to an increase of an
expression level of a
marker gene and its gene product. The term can mean that the expression level
of a certain
marker gene and its gene product in one differentiation stage is increased
compared to another
differentiation stage. "Upregulation of a marker" can also refer to a an
increase of an expression
of a marker gene and its gene product from no (detectable) expression to low,
medium or high
expression of a marker gene and its gene product.
"Expression of marker" means that a certain gene is transcribed into mRNA and
usually is
subsequently translated into a protein (its gene product) which exerts a
certain function in a cell.
The expression of a marker can be detected and quantified on the RNA level or
on the protein
level by methods known in the art. Preferred herein is the detection of the
expression of a marker
CA 02914479 2015-12-03
WO 2015/014731
PCT/EP2014/065991
-22-
on the protein level, e.g. by testing for the presence of a certain protein
with antibodies binding
to the marker.
"Podocytes" are a type of cell located in the kidneys and also known as
glomerular
epithelial cells. Podocytes have a characteristic cell phenotype: They consist
of a main body and
thin extensions that branch out of it and possess characteristics like long
processes, or "foot
projections". As used herein "podocytes" are cells that express at least the
specific surface
marker podocin and the expression of one or more further surface
markers/cellular markers
selected from the group of a-actinin-4, WT1, synaptopodin or nephrin.
Preferred therein are
mature podocytes, i.e. podocytes that do not express the marker PAX2.
Podocin is a glomerular protein which plays a role in the regulation of
glomerular
permeability, and acts as a linker between the plasma membrane and the
cytoskeleton. It is
encoded by NPHS2 (full name nephrosis 2, idiopathic, steroid-resistant
(podocin), NCBI Gene
ID 7827, also known as PDCN or SRN1).
Alpha actinins belong to the spectrin gene superfamily which represents a
diverse group of
cytoskeletal proteins, including the alpha and beta spectrins and dystrophins.
Alpha actinin is an
actin-binding protein with multiple roles in different cell types. In
nonmuscle cells, the
cytoskeletal isoform is found along microfilament bundles and adherens-type
junctions, where it
is involved in binding actin to the membrane. In contrast, skeletal, cardiac,
and smooth muscle
isoforms are localized to the Z-disc and analogous dense bodies, where they
help anchor the
myofibrillar actin filaments. This gene encodes a nonmuscle, alpha actinin
isoform which is
concentrated in the cytoplasm, and thought to be involved in metastatic
processes. Mutations in
this gene have been associated with focal and segmental glomerulosclerosis. a-
actinin-4 is
encoded by ACTN4 (full name actinin, alpha 4, NCBI Gene ID 81, also known as
FSGS; FSGS1;
ACTININ-4).
Synaptopodin is an actin-associated protein that may play a role in actin-
based cell shape
and motility. The name synaptopodin derives from the protein's associations
with postsynaptic
densities and dendritic spines and with renal podocytes. The protein is
encoded by SYNPO
(NCBI Gene ID 11346).
Nephrin is a member of the immunoglobulin family of cell adhesion molecules
that
functions in the glomerular filtration barrier in the kidney. The gene is
primarily expressed in
renal tissues, and the protein is a type-1 transmembrane protein found at the
slit diaphragm of
glomerular podocytes. The slit diaphragm is thought to function as an
ultrafilter to exclude
albumin and other plasma macromolecules in the formation of urine. It is
encoded by Nphsl,
also known as CNF, NPHN or nephrin (NCBI Gene ID 4868). Mutations in this gene
result in
CA 02914479 2015-12-03
WO 2015/014731
PCT/EP2014/065991
-23-
Finnish-type congenital nephrosis 1, characterized by severe proteinuria and
loss of the slit
diaphragm and foot processes.
As used herein, "renal diseases" relates to any disease caused by injury, loss
or dysfunction
of renal cells. Examples for renal diseases are Chronic Kidney Disease (CKD),
Focal segmental
glomerulosclerosis (FSGS), Membranoproliferative glomerulonephritis,
Polycystic kidney
disease (PKD) and diabetic nephropathy associated with Diabetes Type-2.
Further examples are
acute kidney failure/acute kidney injury, Alport syndrome, angiotensin
antibodies and focal
segmental glomerulosclerosis, APOL1 mutations, CFHR5 nephropathy, Bartter
syndrome,
collapsing glomerulopathy, diabetes and diabetic kidney disease related to
CMV, Fabry's disease,
glomerular diseases, HIV-associated nephropathy (HIVAN), lipoprotein
glomerulopathy, lupus
kidney disease, lupus nephritis, membranoproliferative glomerulonephritis,
nodular
glomerulosclerosis, post-infectious glomerulonephritis, post-streptococcal
glomerulonephritis.
References
Batchelder, C.A., Lee, C.C., Matsell, D.G., Yoder, M.C., and Tarantal, A.F.
(2009). Renal
ontogeny in the rhesus monkey (Macaca mulatta) and directed differentiation of
human
embryonic stem cells towards kidney precursors. Differentiation 78, 45-56.
Ok-Hee Chai,Chang-Ho Song, Sung-Kwang Park, Won Kim and Eui-Sic Cho (2013).
Molecular
regulation of kidney development. Anat Cell Biol. 2013 March; 46(1): 19-31.
Humphreys, B.D., and Bonventre, J.V. (2007). The contribution of adult stem
cells to renal
repair. Nephrologie & therapeutique 3, 3-10.
Kim, D., and Dressler, G.R. (2005). Nephrogenic factors promote
differentiation of mouse
embryonic stem cells into renal epithelia. J Am Soc Nephrol 16, 3527-3534.
Lin, S.A., Kolle, G., Grimmond, S.M., Zhou, Q., Doust, E., Little, M.H.,
Aronow, B., Ricardo,
S.D., Pera, M.F., Bertram, J.F., et al. (2010). Subfractionation of
differentiating human
embryonic stem cell populations allows the isolation of a mesodermal
population enriched for
intermediate mesoderm and putative renal progenitors. Stem cells and
development 19, 1637-
1648.
Mae, S., Shirasawa, S., Yoshie, S., Sato, F., Kanoh, Y., Ichikawa, H.,
Yokoyama, T., Yue, F.,
Tomotsune, D., and Sasaki, K. (2010). Combination of small molecules enhances
differentiation
CA 02914479 2015-12-03
WO 2015/014731
PCT/EP2014/065991
-24-
of mouse embryonic stem cells into intermediate mesoderm through BMP7-positive
cells.
Biochemical and biophysical research communications 393, 877-882.
Mae, S., Shono, A., Shiota, F., Yasuno, T., Kajiwara, M., Gotoda-Nishimura,
N., Arai, S., Sato-
Otubo, A., Toyoda, T., Takahashi, K., et al. (2013). Monitoring and robust
induction of
nephrogenic intermediate mesoderm from human pluripotent stem cells. Nat
Commun 4, 1367.
Morizane, R., Monkawa, T., and Itoh, H. (2009). Differentiation of murine
embryonic stem and
induced pluripotent stem cells to renal lineage in vitro. Biochemical and
biophysical research
communications 390, 1334-1339.
Narayanan, K., Schumacher, K.M., Tasnim, F., Kandasamy, K., Schumacher, A.,
Ni, M., Gao, S.,
Gopalan, B., Zink, D., and Ying, J.Y. (2013). Human embryonic stem cells
differentiate into
functional renal proximal tubular-like cells. Kidney international 83, 593-
603.
Ryuichi Nishinakamura, Yukako Uchiyama, Masaji Sakaguchi, Sayoko Fujimura
(2011),
Nephron progenitors in the metanephric mesenchyme. Pediatric Nephrology,
Volume 26, Issue 9,
pp 1463-1467
Nishikawa, M., Yanagawa, N., Kojima, N., Yuri, S., Hauser, P.V., and Jo, O.D.
(2012). Stepwise
renal lineage differentiation of mouse embryonic stem cells tracing in vivo
development.
Biochemical and biophysical research communications 417, 897-902.
Ren, X., Zhang, J., Gong, X., Niu, X., Zhang, X., and Chen, P. (2010).
Differentiation of murine
embryonic stem cells toward renal lineages by conditioned medium from ureteric
bud cells in
vitro. Acta biochimica et biophysica Sinica 42, 464-471.
Song, B., Smink, A.M., Jones, C.V., Callaghan, J.M., Firth, S.D., Bernard,
C.A., Laslett, A.L.,
Kerr, P.G., and Ricardo, S.D. (2012). The directed differentiation of human
iPS cells into kidney
podocytes. PloS one 7, e46453.
Tan, P.P., and Loebel, D.A. (2007). Gene function in mouse embryogenesis: gene
set for
gastrulation. Nat Rev Genet 8, 368-381.
Tiscornia, G., Vivas, E.L., and Belmonte, J.C. (2011). Diseases in a dish:
modeling human
genetic disorders using induced pluripotent cells. Nature Med 17, 1570-1576.
CA 02914479 2015-12-03
WO 2015/014731 PCT/EP2014/065991
-25-
Wiggins, R.C. (2007). The spectrum of podocytopathies: a unifying view of
glomerular diseases.
Kidney international 71, 1205-1214.
EXAMPLES
Materials and Methods
CP21R7: 3 -(3-Amino -p heny1)-4-(1-methy1-1H-indo1-3 -y1)-pyrro le-2,5 -
dione (also
referred to as "compound 21" herein; see e.g. L. Gong et al; Bioorganic&
Medicinal Chemistry
Letters 20 (2010), 1693-1696).
H 0
N
0
----- NH2
0 \ O
\
CP21R7
Cell Culture:
Pluripotency Medium: TeSR1 supplemented with Y27632 ROCK Kinase inhibitor
(commercially available, e.g. Catalogue Number: 1254 from Tocris bioscience).
Priming Medium: 1:1 mixture of DMEM:F12 (1:1) plus Glutamax (Invitrogen) and
Neurobasal
media (N2B27 medium) with N2 and B27 supplements (all Invitrogen), with 1 [iM
CP21R7 (Roche)
and 25 ng/ml BMP4 (Prepotech).
Induction Medium: DMEM:F12 plus Glutamax (Invitrogen) medium supplement with
2.5%
FBS (Life technologies) 0.1 mM non essential amino acid mix (NEAA), 0.1 mM b-
ME, 100 nM
Retinoic Acid (Sigma) and 50 ng/ml BMP7 (Prepotech).
Podocytes Proliferation Medium: DMEM:F12 plus Glutamax (Invitrogen)
supplemented with
10% FBS (Invitrogen), 0.1 mM Retinoic Acid (Sigma) and 100 nM Vitamin D3
(Sigma).
CA 02914479 2015-12-03
WO 2015/014731
PCT/EP2014/065991
-26-
Human ESCs: SA001, LOT CA001 were isolated on March 20, 2001 at Goteborg
University
and Cellartis AB Arvid Wallgrens Backe 20, SE-413 46 Goteborg, SWEDEN follows
all applicable
laws in Sweden and is approved by the Local Research Ethics Committees at
Goteborg University
and Uppsala University. Embryo source: Frozen, surplus from IVF. Donor
confidentiality: In order to
protect the privacy and the confidentiality of the donors, all identifiers
associated with the embryo
donors have been removed. Thus, no information about the donors is accessible.
Notably, the
donation did not result in any financial gain for the donors. We have the
approval to work with
hESCs and to derive different cell lines. The responsible ethical committee
(Ethikkommission beider
Basel) and the Federal office of public health have approved our research
project. (Ref-No: R-FP-S-
1-0002-0000).
Human iPSCs: Catalogue Number: SC101A-1 Lot. Number 110218-FF from SBI System
Biosciences / Catalogue Number: A13777 from Life technologies Gibco Episomal
hiPSC Line.
Human pluripotent stem cells are routinely cultured on hESC-qualified Matrigel
(BD
Bioscience) in TeSR1 medium (Stem cell Technologies). Cultures are passaged
every 4-6 days using
StemPro Accutase (Invitrogen). For an increased viability TeSR1 medium is
supplemented with 10
pM ROCK-inhibitor one hour prior enzymatic dissociation.
1. Method for differentiation of pluripotent stem cells into podocytes
(i) Before the enzymatic dissociation of hPSC colonies using StemPro Accutase
(Invitrogen) cells
were preincubated for one hour with 10 pM ROCK-Inhibitor Y27632. 37.000 single
hPSCs per cm2
were plated onto growth factor reduced Matrigel (BD bioscience) coated cell
culture plates in TeSR1
medium supplemented with 10 pM ROCK-30 Inhibitor.
(ii) On day 1 attachment medium was exchanged to N2B27 (Gibco) medium
supplemented with 1
pM Compound 21 (CP21R7) and 25 ng/ml BMP4 (R&D Systems). Cells were cultivated
for
additional 3 days without media change.
(iii) On day 4 the priming medium was exchanged to DMEMF12 (Gibco) medium
supplemented
with 100 nM retinoic acid (Sigma, R2625) and 50 ng/ml BMP7 (Peprotech). Cells
were cultivated
for additional 2 days without media change.
(vi) On day 6 the cells were dissociated with accutase solution and plated on
collagen I coated plates
at a density of 40000-50000 cells/cm2 in DMEMF12 (Gibco) medium supplemented
with 0.1 mM
CA 02914479 2015-12-03
WO 2015/014731
PCT/EP2014/065991
-27-
retinoic acid (Sigma, R2625) and 100 nM Viatmin D3 (Sigma) for another 7 days.
The proliferation
medium was changed every other day.
2. Immunocytochemistry analysis and image based high content analysis (HCA)
for
Quantification
The cells were fixed with PBS containing 4% paraformaldehyde for 20 min at
room temperature.
After three washing with PBS the cells the cells were then blocked with 5% BSA
solution (Blocking
buffer) for 60 min. When probing for an intracellular antigen, 0.5% Triton-X
was included in the
blocking buffer. The samples were stained with the primary antibody diluted in
2% BSA solution
overnight at 4 C, followed by incubation with the appropriated secondary
antibody for 1 h at room
temperature. Nuclei were stained by DAPI for 5 minutes at room temperature.
Fluorescence was
acquired and analyzed by the Operetta High Content Imaging System (Perkielmer)
followed by
computer-based image analysis (ImageJ, Java-based image processing program).
Separate images
from the same field were acquired using appropriate filters, and exported as
jpg files.
Table with primary antibody used in the work.
Antigen Origin Catalog Number
Bry R&D System AF2085
PAX2 lnvitrogen 716000
LIM1 Abcam Ab14554
SIX2 Proteintech 11562-1-AP
WT1 R&D System AF5729
SALL1 R&D System PP-K9814-00
Actinin-4 Origene TA307264
Podocin Sigma-aldrich P0372
Synaptopodin Abcam Ab101883
ZO-1 lnvitrogen 61-7300
P-cad R&D System MAB861
AQP1 Santa-Cruz sc-20810
CA 02914479 2015-12-03
WO 2015/014731
PCT/EP2014/065991
-28-
3. Functional characterization of iPSCs-derived Podocytes cells
In response to proinflammatory stimuli Podocytes express specific cytokines
including IL-8, Rantes,
MIP-lb and MCP1. Bio-Plex Pro Cytokine, Chemokine and Growth factor assay
(Biorad, M50-
OKCAFOY). After overnight serum starvation hiPS derived podocytes were exposed
at two different
concentrations of TNFa (1 and 5 ng/ml) for 24 hours. After treatment the
supernatants were collected
and used to quantify the Cytokine, Chemokine and Growth factor release using
Bio-Plex Pro
Cytokine, Chemokine and Growth factor assay kit (Biorad, M50-0KCAFOY). The
assay was
performed following the manufacter's instruction. To determine whether the
differentiation system
generates bona fide Podocytes, we challenged the iPS-derived Podocytes with
proinflammatory
TNFa and analyzed for cytokine and chemokine release. Secretome analysis
clearly showed an
increase of the supernatant concentration of IL-8, Rantes, MIP-lb and MCP1 in
a dose dependent
manner, upon TNF-a treatment (Figure 8) comparable to primary human podocytes
(Saleem et al.,
JASN, 2002; data not shown).
